Table 3.
Basic data of these quit patients
| Patient | gender | Age (m) | WBC count (× 109/L) | KMT2Ar subtype | Extramedullary involvement | Blast cell at Day 5 (× 109/L) | D19 | D46 | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BM smear | FCM-MRD (%) | PCR-MRD | BM smear | FCM-MRD (%) | PCR-MRD | |||||||
| 1 | M | 53 | 277.97 | KMT2A-AFF1 | N | 3.776 | CR | 6.21% | Negative | CR | 3.54% | Positive |
| 2 | M | 4 | 652.28 | KMT2A-MLLT1 | TL | 69.0477 | CR | 0.50% | Positive | CR | 0.00% | Positive |
| 3 | M | 145 | 595 | KMT2A-AFF1 | N | 0.8073 | CR | 1.73% | Positive | CR | 0.84% | Positive |
| 4 | F | 7 | 136.08 | KMT2A-AFF1 | N | 0 | CR | 0.00% | Negative | CR | 0.00% | Negative |
| 5 | M | 173 | 191.89 | KMT2A-AFF1 | TL | 0 | CR | 0.04% | Positive | CR | 0.00% | Positive |
| 6 | F | 26 | 23.71 | KMT2-MLLT3 | N | 1.0504 | CR | 9.05% | Positive | CR | 0.11% | Positive |
| 7 | M | 12 | 219.52 | KMT2A-AFF1 | N | 36.7445 | CR | 0.52% | Positive | CR | 0.44% | Positive |